Isomorphic Labs Valuation Could Hit $50bn in a $5bn Funding Round
The DeepMind spinout is still in preclinical stages as it seeks capital to advance its AI drug-design engine toward clinical trials.
5 Articles
5 Articles
Isomorphic Labs valuation could hit $50bn in a $5bn funding round
Isomorphic Labs, the drug discovery company spun out of Google DeepMind, is in talks to raise about $5bn, Bloomberg reported on Wednesday. The round would put the Isomorphic Labs valuation at about $50bn, according to people familiar with the matter. The financing has not closed and the details could change, the people told Rebecca Torrence […] This story continues at The Next Web
Isomorphic Labs in Talks for About $5 Billion in Funding
Alphabet Inc.’s Isomorphic Labs is in talks to raise roughly $5 billion in new funds to support its efforts to use artificial intelligence for drug discovery, according to people familiar with the matter.
Isomorphic Labs, Alphabet's company focused on applying artificial intelligence to drug discovery, talks with investors to capture about $5 billion. The operation could value the firm in $50 billion, although negotiations are not closed and its efforts are still in the preclinical stage.
Coverage Details
Bias Distribution
- 50% of the sources lean Left, 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
